AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock

AbbVie shares slipped below their 50-day moving average after a beat-and-raise quarter—likely due to softer oncology sales and continued weakness in the Aesthetics unit—even as the stock remains above its 200-day SMA and is up ~26% YTD. The company’s recovery from Humira’s patent cliff is being driven by Skyrizi and Rinvoq (combined $18.5bn in sales in the first nine months of 2025, with targets of >$25bn in 2025 and >$31bn by 2027) plus contributions from oncology and neuroscience assets and an active M&A program; Rinvoq’s exclusivity was extended to 2037. Humira biosimilar erosion (sales down >50%) and aesthetics softness have pressured near-term estimates (2025 EPS consensus cut to $10.64), but AbbVie trades at a below-peer forward P/E (~15.8), has raised its dividend, expects mid-single-digit revenue growth in 2025 and a high-single-digit CAGR through 2029, and thus looks positioned for durable, ex-Humira growth—supporting a hold/long-term constructive stance while monitoring execution and consumer demand risks.

Analysis

AbbVie shares slipped below their 50-day simple moving average late last week after a roughly 4% one-month decline and a post-earnings pullback on Oct. 31 despite a beat-and-raise quarter, indicating near-term selling pressure while the stock remains above its 200-day SMA (bull trend intact). The short-term drop was attributed to softer oncology sales and continued weakness in the Aesthetics unit, even as management reiterated mid-single-digit 2025 revenue guidance and reported total revenues up 8.2% in the first nine months of 2025.

The company’s recovery from Humira’s LOE is being driven by Skyrizi and Rinvoq, which together generated $18.5 billion in the first nine months of 2025 (Skyrizi annualizing near $18 billion; Rinvoq >$8 billion) and for which management targets >$25 billion in 2025 and >$31 billion by 2027; Rinvoq exclusivity was extended to 2037. Oncology contributed $5.0 billion (up 2.7% YTD) and neuroscience $7.8 billion (up 20.3% YTD), while Humira sales declined more than 50% YTD and aesthetics sales fell 7.4% with Juvederm down 16.7%.

Valuation and estimate context are mixed: forward P/E of 15.77 is below the industry’s 16.59 and the stock is up 26.1% YTD, but the Zacks 2025 EPS consensus fell from $11.49 to $10.64 amid acquisition-related costs and weaker aesthetics guidance (Aesthetics reduced from $5.1bn to $4.9bn). AbbVie’s active M&A program (30+ deals since 2024), a 5.5% dividend bump and a robust ex-Humira product mix support a constructive long-term view, but near-term execution, consumer-demand sensitivity in Aesthetics and further estimate downgrades are the primary risks to monitor.

Key Decisions for Investors

• Maintain a core position and consider modest add-ins on short-term weakness while the price remains above the 200-day SMA, given strong Skyrizi/Rinvoq momentum, pipeline catalysts and a below-peer forward P/E
• Reassess or trim exposure if the stock breaks decisively below the 200-day SMA or if consensus 2025 EPS continues to be revised materially below $10.64
• Monitor monthly aesthetics trends, oncology sales cadence and any further guidance changes as near-term catalysts or risks, and use deterioration in these metrics as a trigger to reduce risk
• Consider modest downside protection (e.g., options hedges) to guard against macro-driven discretionary spending shocks and acquisition-related cost surprises that could pressure near-term earnings